A Phase I/II, Multi-center, Randomized, Placebo-Controlled, Study Designed to Assess the Safety, Tolerability, and Pharmacokinetics of PTI-428 in Subjects With Cystic Fibrosis
Phase of Trial: Phase I/II
Latest Information Update: 26 Apr 2018
At a glance
- Drugs PTI 428 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; First in man
- Sponsors Proteostasis Therapeutics
- 20 Mar 2018 According to a Proteostasis Therapeutics media release, based on the data from this trial, triple combination study (see profile 292094 ) protocol received endorsement and a high strategic fit score from the Therapeutics Development Network (TDN) and the Clinical Trial Network (CTN) in January 2018.
- 14 Mar 2018 Results published in the Proteostasis Therapeutics media release.
- 12 Mar 2018 Results published in the Proteostasis Therapeutics media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History